A Phase I/IIa Rollover Study of the Whole-Cell Vaccine SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Ipilimumab or Pembrolizumab
Phase of Trial: Phase I/II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary) ; SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon alpha-2b
- Indications Advanced breast cancer
- Focus Adverse reactions; Proof of concept
- Sponsors BriaCell Therapeutics Corp
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.
- 18 Jan 2018 Planned initiation date changed from 15 Dec 2017 to 31 Jan 2018.
- 08 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 15 Dec 2017.